What this study is
(a) To explore the feasibility and utility of implementing broad preemptive pharmacogenomic result delivery in the inpatient setting across multiple institutions specifically with the goal of incorporating minority-specific pharmacogenomic information; (b) To determine whether clinical outcomes for the drug warfarin are improved in African Americans through the availability of pharmacogenomics-based dosing guidance at the point-of-care.
Study details
- Sponsor
- University of Chicago
- Conditions
- Information Seeking Behavior
- Enrolling
- 1,000 people
- Starts
- 2017-11-09
- Est. completion
- 2028-03
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Patients must be at least 18 years of age.
- Patients must self-identify as African American
You can't join if
- Patients who have undergone, or are being actively considered for, liver or kidney transplantation.
- Patients with known active or prior leukemia.
- Inability to understand and give informed consent to participate.
- For patients being recruited to the warfarin sub-study, those with a glomerular filtration rate or creatinine clearance <30 mL/min34.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (2)
2 openThe University of Illinois at Chicago
Chicago, Illinois, United States
- Peter O'Donnell, MD · Contact773-702-7564
Recruiting- Not yet recruiting
Study team
Sponsor
University of Chicago
Study ID IRB17-0890
Principal investigator
Peter O'Donnell, MD
University of Chicago
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.